通络开痹片联合尼美舒利治疗急性痛风性关节炎的临床观察

Clinical observation of Tongluokaibi tablets combined with nimesulide in the treatment of acute gouty arthritis

目的观察通络开痹片联合尼美舒利治疗急性痛风性关节炎的临床疗效。方法选取2017年6月~2018年5月我院ICU治疗的急性痛风性关节炎患者50例,并将其随机分为两组,每组25例。对照组单纯采用尼美舒利治疗,治疗组在对照组的基础上加服通络开痹片;观察两组患者治疗后的综合疗效、疼痛评分、中医证候积分、相关生化指标的变化及不良反应情况。结果治疗后,治疗组总有效率达(92.00%)显著高于对照组(80.00%),差异具有统计学意义(P<0.05);治疗后,治疗组中医证候积分、疼痛评分,ESR、CRP、UA等生化指标水平的改善均显著优于对照组,差异有统计学意义(P<0.05)。两组患者在治疗过程中,均未出现疼痛加剧等不良反应。结论中西医结合治疗痛风性关节炎疗效更好、安全性更高;且虽然血尿酸显著下降,但治疗组未出现急性痛风加重的病例。

Objective To observe the clinical efficacy of Tongluokaibi tablets combined with nimesulide in the treatment of acute gouty arthritis. Methods A total of 50 patients with acute gouty arthritis who were admitted to the ICU in our hospital from June 2017 to May 2018 were selected. They were randomly divided into two groups, 25 cases in each group. Patients in the control group were given nimesulide,while the treatment group was further given Tongluokaibi tablets on the basis of the control group. The comprehensive efficacy, pain score, TCM syndrome scores, related biochemical indicators and adverse reactions of the two groups were observed after treatment. Results After treatment, the total effective rate in the treatment group(92.00%) was significantly higher than that in the control group(80.00%), with statistically significant difference(P<0.05). After treatment, terms of the improvement of TCM syndrome scores, pain score,ESR, CRP, UA and other biochemical indices of the treatment group were significantly better than those in the control group(P<0.05). There was no adverse reactions such as aggravation of pain occurred in the clinical treatment process of both group. Conclusion The combination of traditional Chinese medicine and western medicine in the treatment of gouty arthritis has a better efficacy and higher safety;although the blood uric acid is decreased significantly, there is no case of aggravated acute gout in the treatment group.